Arax Advisory Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5M | Buy |
23,147
+22,632
| +4,395% | +$4.33M | 0.03% | 492 |
|
|
2026
Q1 | $98K | Buy |
515
+260
| +102% | +$47.9K | ﹤0.01% | 1396 |
|
|
2025
Q4 | $44.9K | Sell |
255
-21,126
| -99% | -$3.45M | ﹤0.01% | 1665 |
|
|
2025
Q3 | $3M | Buy |
21,381
+21,048
| +6,321% | +$2.85M | 0.04% | 357 |
|
|
2025
Q2 | $41.8K | Buy |
333
+118
| +55% | +$14.7K | ﹤0.01% | 1326 |
|
|
2025
Q1 | $29.4K | Hold |
215
| – | – | ﹤0.01% | 1144 |
|
|
2024
Q4 | $32.9K | Buy |
+215
| New | +$36.3K | ﹤0.01% | 1022 |
|
|
2024
Q3 | – | Sell |
-20
| Closed | -$4.64K | – | 2626 |
|
|
2024
Q2 | $4.64K | Sell |
20
-5
| -20% | -$1.09K | ﹤0.01% | 1626 |
|
|
2024
Q1 | $5.39K | Buy |
25
+20
| +400% | +$4.68K | ﹤0.01% | 886 |
|
|
2023
Q4 | $1.29K | Hold |
5
| – | – | ﹤0.01% | 1092 |
|
|
2023
Q3 | $1.29K | Hold |
5
| – | – | ﹤0.01% | 1087 |
|
|
2023
Q2 | $1.43K | Hold |
5
| – | – | ﹤0.01% | 1046 |
|
|
2023
Q1 | $1.39K | Hold |
5
| – | – | ﹤0.01% | 1042 |
|
|
2022
Q4 | $1.39K | Hold |
5
| – | – | ﹤0.01% | 1007 |
|
|
2022
Q3 | $1K | Buy |
+5
| New | +$1.06K | ﹤0.01% | 1040 |
|
|
2020
Q4 | – | Sell |
-5
| Closed | -$1K | – | 732 |
|
|
2020
Q3 | $1K | Hold |
5
| – | – | ﹤0.01% | 657 |
|
|
2020
Q2 | $1K | Hold |
5
| – | – | ﹤0.01% | 644 |
|
|
2020
Q1 | $2K | Hold |
5
| – | – | ﹤0.01% | 621 |
|
|
2019
Q4 | $1K | Hold |
5
| – | – | ﹤0.01% | 561 |
|
|
2019
Q3 | $1K | Hold |
5
| – | – | ﹤0.01% | 563 |
|
|
2019
Q2 | $1K | Buy |
+5
| New | +$1.16K | ﹤0.01% | 567 |
|
|
2018
Q4 | $2K | Sell |
5
-12
| -71% | -$3.83K | ﹤0.01% | 524 |
|
|
2018
Q3 | $6K | Sell |
17
-111
| -87% | -$38.2K | ﹤0.01% | 511 |
|
|
2018
Q2 | $37K | Buy |
128
+22
| +21% | +$6.18K | 0.02% | 241 |
|
|
2018
Q1 | $29K | Sell |
106
-60
| -36% | -$18.6K | 0.02% | 251 |
|
|
2017
Q4 | $52K | Sell |
166
-5
| -3% | -$1.6K | 0.02% | 207 |
|
|
2017
Q3 | $53K | Buy |
171
+15
| +10% | +$4.44K | 0.03% | 205 |
|
|
2017
Q2 | $42K | Sell |
156
-32
| -17% | -$8.46K | 0.02% | 244 |
|
|
2017
Q1 | $51K | Buy |
188
+78
| +71% | +$22.1K | 0.02% | 201 |
|
|
2016
Q4 | $31K | Buy |
+110
| New | +$32.6K | 0.02% | 215 |
|
Other funds holding BIIB
Arax Advisory Partners's BIIB Position: Q2 2026 in Review
Arax Advisory Partners increased its Biogen (BIIB) stake by 4,395% in Q2 2026, buying an estimated $4.33M and bringing the position to 23,147 shares worth $5M. The position accounts for 0.03% of the portfolio, ranked #492.
Arax Advisory Partners first reported a position in BIIB in Q4 2016 and has held it in 30 quarters since. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Arax Advisory Partners held 23,147 shares of Biogen worth $5M as of Q2 2026.
- Arax Advisory Partners bought 22,632 Biogen shares in Q2 2026, an estimated $4.33M.
- Biogen made up 0.03% of Arax Advisory Partners's portfolio in Q2 2026, its #492 holding.
- Arax Advisory Partners first reported a position in Biogen in Q4 2016 and has held it in 30 quarters since.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.